Related Experiment Video

Updated: Jun 22, 2025

Simultaneous Measurement of HDAC1 and HDAC6 Activity in HeLa Cells Using UHPLC-MS
09:20

Simultaneous Measurement of HDAC1 and HDAC6 Activity in HeLa Cells Using UHPLC-MS

Published on: August 10, 2017

8.5K

Histone deacetylase 6 as a novel promising target to treat cardiovascular disease

Ya-Xi Wu1, Bing-Qian Li1, Xiao-Qian Yu1

  • 1State Key Laboratory of Esophageal Cancer Prevention and Treatment, Key Laboratory of Advanced Pharmaceutical Technology, Ministry of Education of China, School of Pharmaceutical Science and Institute of Pharmaceutical Science Zhengzhou University Zhengzhou Henan China.

Cancer Innovation
|July 1, 2024
PubMed

Insights

Histone deacetylase 6 (HDAC6) is linked to cardiovascular diseases. This review explores HDAC6 inhibitors for treating conditions like atherosclerosis and heart attack, discussing combination therapies.

Area of Science:

  • Biochemistry
  • Cardiology
  • Epigenetics

Background:

  • Histone deacetylase 6 (HDAC6) is an epigenetic target implicated in tumor and cardiovascular disease links.
  • HDAC6 plays a critical role in regulating various cardiovascular conditions, including atherosclerosis, myocardial infarction, hypertrophy, fibrosis, and hypertension.

Purpose of the Study:

  • To review the association between HDAC6 and cardiovascular disease.
  • To summarize research progress on HDAC6 inhibitors for cardiovascular disease treatment.
  • To discuss the potential of combining HDAC6 inhibitors with other therapies.

Main Methods:

  • Literature review of studies on HDAC6 and cardiovascular disease.
  • Analysis of research on HDAC6 inhibitors' therapeutic effects.
  • Exploration of combination therapy strategies.

Main Results:

  • HDAC6 is a key protein linking tumors and cardiovascular disease.
  • HDAC6 inhibitors show promise in treating cardiovascular diseases.
  • Combination therapies involving HDAC6 inhibitors may offer enhanced efficacy.

Conclusions:

  • HDAC6 is a significant factor in cardiovascular disease pathogenesis.
  • HDAC6 inhibitors represent a potential therapeutic avenue for cardiovascular conditions.
  • Further research into combination therapies is warranted for optimal treatment outcomes.

Keywords:
cardiovascular diseasehistone deacetylase 6inhibitor

More Related Videos

Assays for Validating Histone Acetyltransferase Inhibitors09:11

Assays for Validating Histone Acetyltransferase Inhibitors

Published on: August 6, 2020

6.5K
Purification of H3 and H4 Histone Proteins and the Quantification of Acetylated Histone Marks in Cells and Brain Tissue09:43

Purification of H3 and H4 Histone Proteins and the Quantification of Acetylated Histone Marks in Cells and Brain Tissue

Published on: November 30, 2018

21.3K

Related Concept Videos

Spreading of Chromatin Modifications02:25

Spreading of Chromatin Modifications

The histone proteins in the nucleosomes are post-translationally modified (PTM) to increase or decrease access to DNA. The commonly observed PTMs are methylation, acetylation, phosphorylation, and ubiquitination of lysine amino acids in the histone H3 tail region. These histone modifications have specific meaning for the cell. Hence, they are called "histone code". The protein complex involved in histone modification is termed as "reader-writer" complex.
Writers
The writer...
8.2K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
2.4K